Guanfacine vs Clonidine for ADHD Treatment

Introduction to Guanfacine and Clonidine

Guanfacine is the preferred alpha-2 agonist for ADHD treatment over clonidine due to its superior tolerability profile, specifically its higher alpha-2A receptor specificity resulting in less sedation, better-documented long-term efficacy maintenance, and FDA approval for ADHD monotherapy in the United States 1, 2

Guanfacine demonstrates approximately 10-fold higher specificity for alpha-2A receptors compared to clonidine, which directly translates to fewer sedative effects in clinical practice 1
Guanfacine causes less somnolence and sedation than clonidine, making it more tolerable for daytime functioning 1, 2
Clonidine is primarily metabolized via CYP2D6 with equal renal and hepatic excretion, while guanfacine is metabolized via CYP3A4 with predominantly renal excretion 1

In Europe, guanfacine is approved for ADHD treatment when stimulants are unsuitable, not tolerated, or ineffective, while clonidine is not approved for ADHD treatment at all 1
In the United States, both extended-release formulations are FDA-approved for ADHD as monotherapy or adjunctive to stimulants 1, 2
Guanfacine has well-documented long-term maintenance of treatment effects over 24 months in open-label extension trials 1, 2

Both agents demonstrate medium-range effect sizes compared to placebo, smaller than stimulants, with guanfacine showing effect sizes around 0.7 compared to placebo 1, 2
Common adverse effects include somnolence, fatigue, irritability, insomnia, nightmares, hypotension/bradycardia warnings, and cardiac conduction abnormalities 1, 2
Guanfacine adverse event rates include somnolence (30-39%), headache (20.5-26%), and fatigue (14-15%) 2

Guanfacine extended-release formulation is available in 1, 2, 3, 4 mg tablets, with weight-based dosing of 0.1 mg/kg once daily as a general guideline 1, 2
Clonidine tablets are available in 0.1 and 0.2 mg, with a starting dose of 0.1 mg at bedtime, and a maximum dose of 0.4 mg/day 1

Guanfacine is preferred in first-line scenarios such as comorbid substance use disorders, oppositional defiant disorder, conduct disorder, tic disorders, or Tourette syndrome, and significant sleep disturbances 4
Baseline and ongoing monitoring of blood pressure and heart rate is necessary before initiation and during dose adjustments of both agents 2, 4
Never abruptly discontinue either agent, and taper guanfacine by 1 mg every 3-7 days to avoid rebound hypertension 2, 4

Guanfacine demonstrates improvements in functional impairment and quality of life beyond core ADHD symptoms, sustained over 24 months of treatment 1, 2